|
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
RECRUITINGPhase 1Sponsored by South Plains Oncology Consortium
Actively Recruiting
PhasePhase 1
SponsorSouth Plains Oncology Consortium
Started2013-12
Est. completion2026-12
Eligibility
Age12 Months – 20 Years
Healthy vol.Accepted
Locations5 sites
View on ClinicalTrials.gov →
NCT02013336
Summary
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Eligibility
Age: 12 Months – 20 YearsHealthy volunteers accepted
Inclusion Criteria: * Histologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma * Disease progression after prior therapy in locally advanced or metastatic setting * Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria * Age 12 months to \<21 years * Adequate bone marrow reserves, hepatic function, and renal function * Recovered from effects of any prior surgery or cancer therapy * Patients 18 years or older will provide written consent. A parent or legal guardian of a patient \<18 years of age will provide informed consent and patients 11 to 18 years of age will provide written assent or as per participating institutional policy. Exclusion Criteria: * Clinically significant gastrointestinal disorders * NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure * Active infection or unexplained fever * Known hypersensitivity to any of the components of MM-398 or other liposomal products * Recent Investigational therapy * Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment
Conditions6
CancerEwing SarcomaNeuroblastomaOsteosarcomaRecurrent or Refractory Solid TumorsRhabdomyosarcoma
Locations5 sites
Ohio
1 siteOklahoma
1 siteTexas
2 sitesTexas Tech University Health Sciences Center
Wisconsin
1 siteFind trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorSouth Plains Oncology Consortium
Started2013-12
Est. completion2026-12
Eligibility
Age12 Months – 20 Years
Healthy vol.Accepted
Locations5 sites
View on ClinicalTrials.gov →
NCT02013336